Therapeutic antibody targeting of CD47 eliminates human acute lymphoblastic leukemia

Cancer Research

Volumn 71, Issue 4, 2011, Pages 1374-1384

  Chao, Mark P ^a   Alizadeh, Ash A ^a,b   Tang, Chad ^a   Jan, Max ^a   Weissman Tsukamoto, Rachel ^a   Zhao, Feifei ^a   Park, Christopher Y ^b,c   Weissman, Irving L ^a,b   Majeti, Ravindra ^a,b  

^a STANFORD CANCER INSTITUTE   (United States)

^b STANFORD UNIVERSITY   (United States)

^c MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CD47 MONOCLONAL ANTIBODY; MONOCLONAL ANTIBODY; MONOCLONAL ANTIBODY B6H12.2; UNCLASSIFIED DRUG;

ACUTE LYMPHOBLASTIC LEUKEMIA; ADULT; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIGEN EXPRESSION; ARTICLE; BLOOD; BONE MARROW; BONE MARROW CELL; CONTROLLED STUDY; DRUG TARGETING; FLOW CYTOMETRY; HIGH RISK PATIENT; HUMAN; HUMAN CELL; LEUKEMIA CELL; LIVER; MACROPHAGE; MOUSE; NONHUMAN; PATIENT CARE; PHAGOCYTOSIS; PRIORITY JOURNAL; SPLEEN; SURVIVAL RATE; TREATMENT OUTCOME; TUMOR ENGRAFTMENT;

ADULT; ANIMALS; ANTIBODIES, MONOCLONAL; ANTIGENS, CD47; BONE MARROW TRANSPLANTATION; CELLS, CULTURED; FEASIBILITY STUDIES; HUMANS; IMMUNOTHERAPY; MICE; MOLECULAR TARGETED THERAPY; PRECURSOR CELL LYMPHOBLASTIC LEUKEMIA-LYMPHOMA; REMISSION INDUCTION; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 79951845617     PISSN: 00085472     EISSN: 15387445     Source Type: Journal    
DOI: 10.1158/0008-5472.CAN-10-2238     Document Type: Article

References (39)

1. Pui CH, Relling MV, Downing JR. Acute lymphoblastic leukemia. N Engl J Med 2004;350:1535-48.
2. Smith M, Arthur D, Camitta B, Carroll AJ, Crist W, Gaynon P, et al. Uniform approach to risk classification and treatment assignment for children with acute lymphoblastic leukemia. J Clin Oncol 1996;14:18-24. (Pubitemid 26019992)
3. Schultz KR, Pullen DJ, Sather HN, Shuster JJ, Devidas M, Borowitz MJ, et al. Risk- and response-based classification of childhood Bprecursor acute lymphoblastic leukemia: a combined analysis of prognostic markers from the Pediatric Oncology Group (POG) and Children's Cancer Group (CCG). Blood 2007;109:926-35. (Pubitemid 46220635)
4. Pui CH, Jeha S. New therapeutic strategies for the treatment of acute lymphoblastic leukaemia. Nat Rev Drug Discov 2007;6:149-65. (Pubitemid 46758753)
5. Majeti R, Chao MP, Alizadeh AA, Pang WW, Jaiswal S, Gibbs KD Jr, et al. CD47 is an adverse prognostic factor and therapeutic antibody target on human acute myeloid leukemia stem cells. Cell 2009;138:286-99.
6. Blazar BR, Lindberg FP, Ingulli E, Panoskaltsis-Mortari A, Oldenborg PA, Iizuka K, et al. CD47 (integrin-associated protein) engagement of dendritic cell and macrophage counterreceptors is required to prevent the clearance of donor lymphohematopoietic cells. J Exp Med 2001;194:541-9. (Pubitemid 32835048)
7. Okazawa H, Motegi S, Ohyama N, Ohnishi H, Tomizawa T, Kaneko Y, et al. Negative regulation of phagocytosis in macrophages by the CD47-SHPS-1 system. J Immunol 2005;174:2004-11. (Pubitemid 40223942)
8. Oldenborg PA, Zheleznyak A, Fang YF, Lagenaur CF, Gresham HD, Lindberg FP, et al. Role of CD47 as a marker of self on red blood cells. Science 2000;288:2051-4. (Pubitemid 30397687)
9. Oldenborg PA, Gresham HD, Lindberg FP. CD47-signal regulatory protein alpha (SIRPalpha) regulates Fcgamma and complement receptor-mediated phagocytosis. J Exp Med 2001;193:855-62.
10. Barclay AN, Brown MH. The SIRP family of receptors and immune regulation. Nat Rev Immunol 2006;6:457-64.
11. Jaiswal S, Jamieson CH, Pang WW, Park CY, Chao MP, Majeti R, et al. CD47 is upregulated on circulating hematopoietic stem cells and leukemia cells to avoid phagocytosis. Cell 2009;138:271-85.
12. Chan KS, Espinosa I, Chao M, Wong D, Ailles L, Diehn M, et al. Identification, molecular characterization, clinical prognosis, and therapeutic targeting of human bladder tumor-initiating cells. Proc Natl Acad Sci U S A 2009;106:14016-21.
13. Chao MP, Alizadeh AA, Tang C, Myklebust JH, Varghese B, Gill S, et al. Anti-CD47 antibody synergizes with rituximab to promote phagocytosis and eradicate non-Hodgkin lymphoma. Cell 2010;142:699-713.
14. Willman CL. Discovery of novel molecular classification schemes and genes predictive of outcome in leukemia. Hematol J 2004;5Suppl3:S138-43.
15. Yeoh EJ, Ross ME, Shurtleff SA, Williams WK, Patel D, Mahfouz R, et al. Classification, subtype discovery, and prediction of outcome in pediatric acute lymphoblastic leukemia by gene expression profiling. Cancer Cell 2002;1:133-43. (Pubitemid 41039160)
16. Holleman A, den Boer ML, Cheok MH, Kazemier KM, Pei D, Downing JR, et al. Expression of the outcome predictor in acute leukemia 1 (OPAL1) gene is not an independent prognostic factor in patients treated according to COALL or St Jude protocols. Blood 2006;108:1984-90. (Pubitemid 44395011)
17. Miller R, Siegmund D. Maximally selected chi square statistics. Biometrics 1982;38:1011-6. (Pubitemid 14272808)
18. Kang H, Chen IM, Wilson CS, Bedrick EJ, Harvey RC, Atlas SR, et al. Gene expression classifiers for relapse-free survival and minimal residual disease improve risk classification and outcome prediction in pediatric B-precursor acute lymphoblastic leukemia. Blood 115;1394-405.
19. Takenaka K, Prasolava TK, Wang JC, Mortin-Toth SM, Khalouei S, Gan OI, et al. Polymorphism in Sirpa modulates engraftment of human hematopoietic stem cells. Nat Immunol 2007;8:1313-23. (Pubitemid 350138972)
20. Subramanian S, Parthasarathy R, Sen S, Boder ET, Discher DE. Species- and cell type-specific interactions between CD47 and human SIRPalpha. Blood 2006;107:2548-56. (Pubitemid 43348703)
21. Till MM, Hardisty RM, Pike MC. Long survivals in acute leukaemia. Lancet 1973;1:534-8.
22. Onciu M, Lai R, Vega F, Bueso-Ramos C, Medeiros LJ. Precursor Tcell acute lymphoblastic leukemia in adults: age-related immunophenotypic, cytogenetic, and molecular subsets. Am J Clin Pathol 2002;117:252-8. (Pubitemid 34823666)
23. Reinhold MI, Lindberg FP, Plas D, Reynolds S, Peters MG, Brown EJ, et al. In vivo expression of alternatively spliced forms of integrin-associated protein (CD47). J Cell Sci 1995;108:3419-25.
24. Fadok VA, Voelker DR, Campbell PA, Bratton DL, Cohen JJ, Noble PW, et al. Exposure of phosphatidylserine on the surface of apoptotic lymphocytes triggers specific recognition and removal by macrophages. J Immunol 1992;148:2207-16.
25. Scannell M, Flanagan MB, deStefani A, Wynne KJ, Cagney G, Godson C, Maderna P. Annexin-1 and peptide derivatives are released by apoptotic cells and stimulate phagocytosis of apoptotic neutrophils by macrophages. J Immunol 2007;178:4595-605. (Pubitemid 46492412)
26. Gardai SJ, McPhillips KA, Frasch SC, Janssen WJ, Starefeldt A, Murphy-Ullrich JE. Cell-surface calreticulin initiates clearance of viable or apoptotic cells through trans-activation of LRP on the phagocyte. Cell 2005;123:321-34. (Pubitemid 41457220)
27. Jeha S. New therapeutic strategies in acute lymphoblastic leukemia. Semin Hematol 2009;46:76-88.
28. Thomas DA, Faderl S, O'Brien S, Garcia-Manero G, Ferrajoli A, Wierda W, et al. Chemoimmunotherapy with hyper-CVAD plus rituximab for the treatment of adult Burkitt and Burkitt-type lymphoma or acute lymphoblastic leukemia. Cancer 2006;106:1569-80.
29. Gokbuget N, Hoelzer D. Novel antibody-based therapy for acute lymphoblastic leukaemia. Best Pract Res Clin Haematol 2006;19:701-13. (Pubitemid 44418029)
30. Raetz EA, Cairo MS, Borowitz MJ, Blaney SM, Krailo MD, Leil TA, et al. Chemoimmunotherapy reinduction with epratuzumab in children with acute lymphoblastic leukemia in marrow relapse: a Children's Oncology Group Pilot Study. J Clin Oncol 2008;26:3756-62.
31. Herrera L, Bostrom B, Gore L, Sandler E, Lew G, Schlegel PG, et al. A phase 1 study of Combotox in pediatric patients with refractory B-lineage acute lymphoblastic leukemia. J Pediatr Hematol Oncol 2009;31:936-41.
32. Wayne AS, Kreitman RJ, Findley HW, Lew G, Delbrook C, Steinberg SM, et al. Anti-CD22 immunotoxin RFB4(dsFv)-PE38 (BL22) for CD22-positive hematologic malignancies of childhood: preclinical studies and phase I clinical trial. Clin Cancer Res 2010;16:1894-903.
33. Du X, Beers R, Fitzgerald DJ, Pastan I. Differential cellular internalization of anti-CD19 and -CD22 immunotoxins results in different cytotoxic activity. Cancer Res 2008;68:6300-5.
34. Uckun FM, Messinger Y, Chen CL, O'Neill K, Myers DE, Goldman F, et al. Treatment of therapy-refractory B-lineage acute lymphoblastic leukemia with an apoptosis-inducing CD19-directed tyrosine kinase inhibitor. Clin Cancer Res 1999;5:3906-13. (Pubitemid 30013764)
35. Gokbuget N, Hoelzer D. Treatment with monoclonal antibodies in acute lymphoblastic leukemia: current knowledge and future prospects. Ann Hematol 2004;83:201-5. (Pubitemid 38443503)
36. Ottmann OG,Wassmann B. Imatinib in the treatment of Philadelphia chromosome-positive acute lymphoblastic leukaemia: current status and evolving concepts. Best Pract Res Clin Haematol 2002;15:757-69.
37. Thomas DA, Faderl S, Cortes J, O'Brien S, Giles FJ, Kornblau SM, et al. Treatment of Philadelphia chromosome-positive acute lymphocytic leukemia with hyper-CVAD and imatinib mesylate. Blood 2004;103:4396-407. (Pubitemid 38745962)
38. Alinari L, Lapalombella R, Andritsos L, Baiocchi RA, Lin TS, Byrd JC, et al. Alemtuzumab (Campath-1H) in the treatment of chronic lymphocytic leukemia. Oncogene 2007;26:3644-53. (Pubitemid 46842714)
39. Angiolillo AL, Yu AL, Reaman G, Ingle AM, Secola R, Adamson PC, et al. A phase II study of Campath-1H in children with relapsed or refractory acute lymphoblastic leukemia: a Children's Oncology Group report. Pediatr Blood Cancer 2009;53:978-83.